Daniel Lesueur Sells 5,209 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total transaction of $30,003.84. Following the transaction, the chief operating officer now directly owns 86,044 shares in the company, valued at approximately $495,613.44. This represents a 5.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Daniel Lesueur also recently made the following trade(s):

• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $5.70 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business has a 50-day moving average of $6.86 and a 200-day moving average of $7.43. The stock has a market capitalization of $346.83 million, a price-to-earnings ratio of -4.22 and a beta of 1.34. Health Catalyst, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $10.31.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period last year, the company posted ($0.22) earnings per share. As a group, sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently added to or reduced their stakes in HCAT. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares during the period. Primecap Management Co. CA grew its holdings in Health Catalyst by 1.1% during the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after purchasing an additional 25,000 shares during the period. Nepsis Inc. increased its position in Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after buying an additional 851,448 shares during the last quarter. Geode Capital Management LLC raised its stake in Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after buying an additional 66,896 shares during the period. Finally, State Street Corp lifted its position in shares of Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after buying an additional 28,251 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Citigroup dropped their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Finally, Canaccord Genuity Group cut their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.60.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.